Press ESC to close

ELISA

11 Articles
0 855
8

As summer approaches, cases of Tick-borne diseases (TBDs) are on the rise. Lyme disease (LD) is the most common TBD and is generally cured with antibiotic treatment. Testing relies on detecting a patient’s immune response to infection. However, diagnosis of LD can be challenging. Optimal diagnostic accuracy of LD can be achieved by combining two separate antibody tests with consideration of a patient’s symptoms and tick exposure.

0 2332
6

Bartonellosis is an infectious disease caused by Bartonella species and is implicated in causing many emerging and re-emerging infections globally. While there are multiple species, the three most common Bartonella species (and the infections they cause) are: Bartonella henselae (Cat Scratch Disease), Bartonella quintana (Trench fever), and Bartonella bacilliformis (Oroya fever).

0 2009
7

KOL Spotlight Interviews is a segment where we interview experts in various fields on their expertise and insights that continue to help shape the diagnostics and pharmaceutical industries. This month, we have the pleasure of welcoming Dr. Animesh Sinha, a renowned dermatologist from University at Buffalo. Below, we will learn more about diagnostic methods for autoimmune bullous dermatoses conditions.

7 3038
6

Meet Lisa Ann, a patient who was diagnosed with a rare autoimmune skin blistering disease after many misdiagnoses. She shares her story from the first symptoms and frustrations, testing and multiple doctor visits, and how she lives and manages this condition today. Check out this Patient Journey to hear from Lisa Ann and learn what diagnostic tests are available for these rare skin diseases.

0 1568
7

Invasive Aspergillosis (IA) is an infection caused by Aspergillus. People with weakened immune systems or lung diseases are at a higher risk of developing IA. It is one of the most commonly under-detected diagnoses in ICU patients. Because symptoms are not specific, it is important to know which diagnostic tests can aid in early detection and management of IA.

0 4070
6

There is a need for continuous monitoring of therapeutic levels of TNF-α inhibitors to promote individualized treatment while affirming that patients receive the most accurate and cost-effective regimen available. With the MabTrack ELISA, clinicians can make effective adjustments based on semi-quantitative results and can facilitate simplified decision-making with their patients for improved long-term response.